These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22685658)

  • 1. Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.
    Nishimura T; Kato H; Ikeda N; Kihara M; Nomura M; Kato Y; Marko-Varga G
    Int J Proteomics; 2012; 2012():921901. PubMed ID: 22685658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare.
    Kato H; Nishimura T; Hirano T; Nomura M; Tojo H; Fujii K; Kawamura T; Mikami S; Kihara M; Bando Y; Tsuboi M; Ikeda N; Marko-Varga G
    J Proteome Res; 2011 Jan; 10(1):51-7. PubMed ID: 21141868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
    Marko-Varga G; Fehniger TE; Rezeli M; Döme B; Laurell T; Végvári A
    J Proteomics; 2011 Jun; 74(7):982-92. PubMed ID: 21440690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments for a growing Japanese patient population: facilitating new technologies for future health care.
    Kato H; Nishimura T; Ikeda N; Yamada T; Kondo T; Saijo N; Nishio K; Fujimoto J; Nomura M; Oda Y; Lindmark B; Maniwa J; Hibino H; Unno M; Ito T; Sawa Y; Tojo H; Egawa S; Edula G; Lopez M; Wigmore M; Inase N; Yoshizawa Y; Nomura F; Marko-Varga G
    J Proteomics; 2011 May; 74(6):759-64. PubMed ID: 21184850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
    Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
    Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.
    Yamauchi M; Gotoh N
    Biomark Med; 2009 Apr; 3(2):139-51. PubMed ID: 20477507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
    Hsu JC; Wei CF; Yang SC
    BMJ Open; 2019 Mar; 9(3):e022293. PubMed ID: 30878976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
    Haber DA; Settleman J
    Cell Cycle; 2005 Aug; 4(8):1057-9. PubMed ID: 15970680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of EGFR inhibitors in nonsmall cell lung cancer.
    Ciardiello F; De Vita F; Orditura M; Tortora G
    Curr Opin Oncol; 2004 Mar; 16(2):130-5. PubMed ID: 15075904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy.
    Taube SE; Abrams JS
    Per Med; 2005 Nov; 2(4):363-369. PubMed ID: 29788577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.